Alembic Pharma rating – Hold: India sales bright spot of Q3FY21

on
Execution key for India and US sales; FY21-22e EPS up 3%; valuations factor in prospects; ‘Hold’ retained

from The Financial Express https://ift.tt/3a2PJwT
https://ift.tt/eA8V8J HSBC

Comments

Post a Comment